Pharmacoeconomics and quality of life analysis of telmisartan in hypertension treatment

References

• Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science274, 740–743 (1996).
   PubMed Web of Science ®Google Scholar
• Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension. A research success story. Arch. Intern. Med.156, 1926–1935 (1996).
   Google Scholar
• Chobanian AV, Bakris GL, Black HR et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Singh RB, Suh IL, Singh VP et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. Hum. Hypertens.14, 749–763 (2000).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation104, 2746–2753 (2001).
   PubMed Web of Science ®Google Scholar
• Brown CD, Higgins M, Donato KA et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes. Res.8, 605–619 (2000).
   PubMedGoogle Scholar
• Cupples LA, D’Agostino RB, Kiely D. The Framingham Study. An Epidemiological Investigation of Cardiovascular Disease, Section 34. Some of the risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. National Heart, Lung and Blood Institute MD, USA (1987).
   Google Scholar
• Klungel OH, Stricker BH, Paes AH et al. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. Stroke30, 1312–1318 (1999).
   PubMed Web of Science ®Google Scholar
• Redon J. The normal circadian pattern of blood pressure: implications for treatment. Int. J. Clin. Pract.58(Suppl. 145), 3–8 (2004).
   Web of Science ®Google Scholar
• Weber MA. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? Am. J. Cardiol.89(Suppl. 2A), 27–33A (2002).
   PubMed Web of Science ®Google Scholar
• Dzau V. The cardiovascular continuum and renin–angiotensin–aldosterone system blockade. J. Hypertens.23(Suppl. 1), S9–S17 (2005).
   Google Scholar
• Chrysant SG, Chrysant GS, Desai A. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J. Hum. Hypertens.19(3), 173–183 (2005).
   Google Scholar
• Bakris GL, Mensah GA. Pathogenesis and clinical physiology of hypertension. Cardiol. Clin.20(2), 195–206 (2002).
   PubMedGoogle Scholar
• Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs61(10), 1501–1529 (2001).
   PubMed Web of Science ®Google Scholar
• Clark R. Drug review – telmisartan. Drugs in Context Primary Care Part B: Cardiovascular Medicine II1(6), 229–246 (2004).
   Google Scholar
• Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020, Global Burden of Disease Study. Lancet349, 1498–1504 (1997).
   PubMed Web of Science ®Google Scholar
• American Heart Association. 2002 Heart and Stroke Statistical Update. American Heart Association TX, USA (2001).
   Google Scholar
• Rosamond W, Flegal K, Friday G et al; Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation115(5), 69–171 (2007).
   PubMed Web of Science ®Google Scholar
• Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European Cardiovascular Disease Statistics. Joint publication by the British Heart Foundation, European Heart Network and the Health Economics Research Centre at the University of Oxford, Oxford, UK (2005).
   Google Scholar
• Leal J, Luengo-Fernandez R, Gray A et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J.27, 1610–1619 (2006).
   PubMed Web of Science ®Google Scholar
• Khan JM, Beevers DG. Management of hypertension in ethnic minorites. Heart91(8), 1105–1109 (2005).
   Google Scholar
• Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin. Ther.19, 1446–1457 (1997).
   PubMed Web of Science ®Google Scholar
• Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J. Hum. Hypertens.12, 533–537 (1998).
   PubMed Web of Science ®Google Scholar
• Kirch W, Horn B, Schweizer J. Comparison of angiotensin II receptor antagonists. Eur. J. Clin. Invest.31(8), 698–706 (2001).
   PubMed Web of Science ®Google Scholar
• Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press.10(Suppl.), 6–11 (2001).
   PubMedGoogle Scholar
• Scheen AJ. Renin–angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab.30(6) 487–496 (2004).
   PubMed Web of Science ®Google Scholar
• Abuissa H, Jones PG, Marso SP et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol.46(5), 821–826 (2005).
   PubMed Web of Science ®Google Scholar
• Gillespie EL, White CM, Kardas M et al. The impact of ACE inhibitors or angiotensin II Type 1 receptor blockers on the development of new-onset Type 2 diabetes. Diabetes Care28(9), 2261–2266 (2005).
   PubMed Web of Science ®Google Scholar
• Schrader J, Lüders S, Kulschewski A et al.; for the MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke36, 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al.; for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J. Hypertens.21, 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Schrader J, Lüders S, Kulschewski A et al. on behalf of the ACCESS Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke34, 1699–1703 (2003).
   PubMed Web of Science ®Google Scholar
• Bloch MJ, Basile J. Defining the role of angiotensin receptor blocker therapy in Japanese persons with underlying vascular disease: the Jikei Heart Study. J. Clin. Hypertens.9(7), 576–579 (2007).
   Google Scholar
• Fukui T, Rahman M, Morita S, Sakamoto J. Informed consent in the Candesartan Anthiypertensive Survival Evaluation in Japan (CASE-J) trial: a survey of collaborating physicians. Hypertens. Res.29(7), 471–474 (2006).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux R, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE Study Group. Am. J. Hypertens.10, 705–713 (1997).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet363, 2049–2051 (2004).
   PubMed Web of Science ®Google Scholar
• Teo K, Yusuf S, Sleight P et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am. Heart J.148, 52–61 (2004).
   PubMed Web of Science ®Google Scholar
• de Gasparo M. AT1 receptor antagonists: pharmacology. In: Part 5. Inhibition of the Renin-Angiotensin System. Angiotensin – Vol. II. Series: Handbook of Experimental Pharmacology (Vol. 163) Unger T, Schölkens BA (Eds). Springer Verlag, Heidelberg, Germany 417–452 (2004).
   Google Scholar
• Kakuta H, Sudoh K, Sasamata M et al. Telmisartan has the strongest binding affinity to angiotensin II type I receptor: comparison with other angiotensin II type 1 receptor blockers. Int. J. Clin. Pharmacol. Res.25(1), 41–46 (2005).
   PubMedGoogle Scholar
• Maillard MP, Perregaux C, Centeno C et al.In vitro and in vivo characterization of the activity of telmisartan : an insurmountable angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther.302(3), 1089–1095 (2002).
   PubMed Web of Science ®Google Scholar
• Stangier J, Su C-APF, van Heiningen PNM et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J. Cardiovasc. Pharmacol.38(5), 672–685 (2001).
   PubMed Web of Science ®Google Scholar
• Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J. Hypertens.17(2), 293–302 (1999).
   PubMed Web of Science ®Google Scholar
• Smith DH, Matzek KM. Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J. Clin. Pharmacol.40(12 Pt 1), 1380–1390 (2000).
   PubMed Web of Science ®Google Scholar
• Schupp M, Janke J, Clasen R et al. Angiotensin Type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation109(17), 2054–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-γ-modulating activity. Hypertension43(5), 993–1002 (2004).
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Masuzaki H, Tanaka T et al. An angiotensin II AT1 receptor antagonist, telmisartan, augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett.576(3), 492–497 (2004).
   PubMed Web of Science ®Google Scholar
• Fogari R, Lazzari P, Zoppi A et al. Effect of telmisartan, losartan, and lisinopril on insulin sensitivity in hypertensive patients with and without insulin resistance. Eur. Heart J.25, 78 (2004) (Abstract P525).
   Google Scholar
• Battershill AJ, Scott LJ. Telmisartan – a review of its use in the management of hypertension. Drugs66(1), 52–83 (2006).
   Google Scholar
• Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J. Hum. Hypertens.14(Suppl. 1), S73–S86 (2000).
   PubMed Web of Science ®Google Scholar
• Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet355(9204), 637–645 (2000).
   PubMed Web of Science ®Google Scholar
• Hasford J. Compliance and benefit/risk relationship of antihypertensive treament. J. Cardiovasc. Pharmacol.20(Suppl. 6), S30–S34 (1992).
   Google Scholar
• Mancia G, Lanfranchi A, Cattaneo BM, Grassi G. Hypertension – when is the clinical problem solved? When patients are rendered normotensive. Cardiology85(Suppl. 1), 58–64 (1994).
   PubMedGoogle Scholar
• Li W, Liu L, Puente JG et al. Hypertension and health-related quality of life: an epidemiological study in patients attending hospital clinics in China. J. Hypertens.23, 1667–1676 (2005).
   PubMed Web of Science ®Google Scholar
• Stewart AL, Greenfield S, Hays RD et al. Functional status and well-being of patients with chronic conditions. JAMA269, 907–913 (1989).
   Google Scholar
• Bulpitt CJ, Dollery CT, Carne S. Change in symptoms of hypertensive patients after referral to hospital clinic. Br. Heart J.38, 121–128 (1976).
   PubMedGoogle Scholar
• Kjellgren K, Ahlner J, Dahlof B et al. Perceived symptoms amongst hypertensive patients in routine clinical practice – a population-based study. J. Intern. Med.244, 325–332 (1998).
   PubMed Web of Science ®Google Scholar
• Moller L, Kristensen TS, Hollnagel H. Self rated health as a predictor of coronary heart disease in Copenhagen, Denmark. J. Epidemiol. Community Health50, 423–428 (1996).
   PubMed Web of Science ®Google Scholar
• Kottke T, Tuomiletho J, Puska P et al. The relationship of symptoms and blood pressure in a population sample. Int. J. Epidemiol.8, 355–359 (1979).
   PubMed Web of Science ®Google Scholar
• Weber MA, Bakris GL, Neutel JM et al. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J. Clin. Hypertens.5(5), 322–329 (2003).
   PubMedGoogle Scholar
• Galzerano D, Tammaro P, Cerciello A et al. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J. Hum. Hypertens.18, 53–59 (2004).
   PubMed Web of Science ®Google Scholar
• Freytag F, Schelling A, Meinicke T et al. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin. Ther.23(1), 108–123 (2001).
   PubMed Web of Science ®Google Scholar
• Richter A, Gondek K, Ostrowski C et al. Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs. Manag. Care Interface61–69 (2001).
   Google Scholar